Editorial Comment: Identification of a Highly Sensitive Combination of Urinary Protein Biomarkers for the Detection of High-Grade Bladder Cancer

The study by Bouchard et al1 examines the performance characteristics of a rigorous proteomic discovery platform and includes validation in an independent cohort using a 4-protein urinary panel—CFH, FGB, A2M, and AMY2A—that demonstrates exceptional sensitivity (100%, sample size 104) for high-grade disease. Their ability to reach such accuracy, including in nonmuscle invasive lesions, highlights promising potential for noninvasive testing to address long-standing limitations surrounding bladder cancer surveillance. A strength of their findings is maintaining sensitivity and specificity among urine samples indiscriminately containing hematuria or benign inflammation. This better reflects real-world populations and delivers where other urinary tests have failed because of lack of consistent performance.2 However, the developed urinary protein assay fails to reach the author's predetermined specificity goal among the remission group (those with a history of bladder cancer), perpetuating a limitation of past urinary protein assays: their poor performance for disease surveillance.3 Also, the study's limited sample size (97 for discovery, 104 for validation) and retrospective design position it more as a starting point for future research as a functional tool in clinical practice. Finally, the ultimate utility of a urinary diagnostic marker should be tested in a randomized controlled trial: Does use of the marker improve an important outcome such as disease stage, survival, quality of life, or cost? These types of studies, though rare, remain the gold standard for practice modification.